THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY

HOME
VYEPTI
RESOURCES
REPORT AN ADVERSE EVENT
PRESCRIBING INFORMATION

VYEPTI® (EPTINEZUMAB) IS INDICATED FOR THE PROPHYLAXIS OF MIGRAINE IN ADULTS WHO HAVE AT LEAST 4 MIGRAINE DAYS PER MONTH¹
PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING CAN BE ACCESSED VIA THE TABS AT THE TOP OF THIS PAGE

GET IN TOUCH/HERE TO HELP

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Lundbeck Limited,
on: 01908 638972 or Email: SafetyLuUnitedKingdom@lundbeck.com

Reference